Findings

What do systematic reviews say?

748 questions · 782 findings · 58 reviews · Gynaecological, Neuro-oncology and Orphan Cancer

Sort:Best matchNewest Highest certainty Download CSV

No studies found 164 · 21%GRADE not reported 26 · 3.3%Very low 151 · 19.3%Low 222 · 28.4%Moderate 158 · 20.2%High 61 · 7.8%

Corticosteroids vs placebo

Mean GI symptom scores · Men with prostate cancer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Corticosteroids vs placebo

Acute and late GI toxicity (grade 2+) · Men with prostate cancer

It is very uncertain whether summary of findings: Corticosteroids changes acute and late GI toxicity (grade 2+) compared with placebo (very low certainty).

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
RR 0.85 [0.62, 1.15]
1 study · 126 participants
Very low

Corticosteroids vs placebo

Diarrhoea (grade 2+) · Men with prostate cancer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Corticosteroids vs placebo

QoL · Men with prostate cancer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Amifostine vs no intervention

Mean GI symptom scores · People with urological, gynaecological or colorectal cancer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: IMRT vs 3DCRT

Mean GI symptom scores (EORTC‐QLQPR25 scale; lower scores better) · People with urological (prostate) and gynaecological (cervical) cancer

Summary of findings: IMRT showed no clear difference in mean GI symptom scores (EORTC‐QLQPR25 scale; lower scores better) compared with 3DCRT (low certainty).

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 181 participants
Low

Amifostine vs no intervention

Acute and late GI toxicity (grade 2+) · People with urological, gynaecological or colorectal cancer

Summary of findings: Amifostine may leads to lower acute and late GI toxicity (grade 2+) compared with no intervention (low certainty).

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
RR 0.25
3 studies · 278 participants
Low

Amifostine vs no intervention

Diarrhoea (grade 2+) · People with urological, gynaecological or colorectal cancer

It is very uncertain whether summary of findings: Amifostine changes diarrhoea (grade 2+) during treatment compared with no intervention (very low certainty).

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
RR 0.25 [0.06, 0.98]
1 study · 36 participants
Very low

Amifostine vs no intervention

QoL · People with urological, gynaecological or colorectal cancer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: Sodium butyrate vs placebo

Mean GI symptom scores · Men undergoing RT for prostate cancer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: Sodium butyrate vs placebo

Acute and late GI toxicity (grade 2+) · Men undergoing RT for prostate cancer

Summary of findings: Sodium butyrate showed no clear difference in acute and late GI toxicity (grade 2+) compared with placebo (moderate certainty).

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
RR 0.91 [0.41, 1.98]
1 study · 79 participants
Moderate

Summary of findings: Sodium butyrate vs placebo

Diarrhoea (grade 2+) · Men undergoing RT for prostate cancer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: Sodium butyrate vs placebo

QoL · Men undergoing RT for prostate cancer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Selenium vs no intervention

Mean GI symptom scores · Women undergoing RT for gynecological cancer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Selenium vs no intervention

Acute and late GI toxicity (grade 2+) · Women undergoing RT for gynecological cancer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Selenium vs no intervention

Diarrhoea (grade 2+) · Women undergoing RT for gynecological cancer

Summary of findings: Selenium may leads to lower diarrhoea (grade 2+) compared with no intervention (low certainty).

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
RR 0.4
1 study · 81 participants
Low

Summary of findings: IMRT vs 3DCRT

Acute and late GI toxicity (grade 2+) · People with urological (prostate) and gynaecological (cervical) cancer

Summary of findings: IMRT may leads to lower acute and late GI toxicity Grade 2+ compared with 3DCRT (low certainty).

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
RR 0.48 [0.26, 0.88]
4 studies · 444 participants
Low

Selenium vs no intervention

QoL · Women undergoing RT for gynecological cancer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: Bile acid sequestrants vs no intervention

Mean GI symptom scores (during RT) · People with pelvic cancer

It is very uncertain whether summary of findings: Bile acid sequestrants changes mean GI symptom scores (during RT) compared with no intervention (very low certainty).

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
MD 0.5
1 study · 33 participants
Very low

Summary of findings: Bile acid sequestrants vs no intervention

Acute and late GI toxicity (grade 2+) · People with pelvic cancer

Summary of findings: Bile acid sequestrants may leads to higher acute and late GI toxicity (grade 2+) compared with no intervention (low certainty).

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
RR 4.24 [1.07, 16.7]
1 study · 33 participants
Low